KURN — Kuros Biosciences AG Share Price
Last trade - 00:00- CH₣883.88m
- CH₣872.07m
- $146.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 102.09 | ||
| PEG Ratio (f) | 1.55 | ||
| EPS Growth (f) | 192.69% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.1 | ||
| Price to Tang. Book | 25.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.58 | ||
| EV to EBITDA | 88.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.76% | ||
| Return on Equity | 3.31% | ||
| Operating Margin | 6.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.12 | 18.84 | 37.36 | 85.16 | 146.06 | 250.47 | 320.6 | 102.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +378.96 | +68.42 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kuros Biosciences AG is a Switzerland‑based biotechnology company engaged in the research, development, and commercialization of biologic technologies for musculoskeletal care, with a focus on those supporting bone regeneration and bone growth. The Company's key product is MagnetOs, which is a synthetic bone graft technology available in multiple formats such as granules or putty. MagnetOs is designed to stimulate bone formation, including through mechanisms that engage the body’s immune response. The technology behind MagnetOs is associated with osteoimmunology, which involves immune‑modulated bone healing. MagnetOs uses the proprietary NeedleGrip submicron surface technology, which supports bone growth by enhancing biological responses related to healing. It is indicated for use across the skeletal system and is positioned as a bone graft option for procedures involving various anatomical regions.
Directors
- Clemens van Blitterswijk NEC (64)
- Joost de Bruijn CEO (55)
- Leanna Caron NVC (51)
- Michael Grau CFO (55)
- Alistair Irvine EXB (48)
- Pascal Longlade EXB (59)
- Philippe Saudan EXB (50)
- Frank-Jan van der Velden EXB (62)
- Scott Bruder NED (59)
- Oliver Walker NED (52)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- March 3rd, 1995
- Public Since
- October 29th, 2002
- No. of Employees
- 178
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 39,179,277
- Address
- Wagistrasse 25, SCHLIEREN, 8952
- Web
- https://kurosbio.com/
- Phone
- +41 447334747
- Auditors
- PricewaterhouseCoopers AG
Latest News for KURN
Upcoming Events for KURN
Q1 2026 Kuros Biosciences AG Trading Statement Release
Kuros Biosciences AG Annual Shareholders Meeting
Kuros Biosciences AG Annual Shareholders Meeting
Kuros Biosciences AG Capital Markets Day
Half Year 2026 Kuros Biosciences AG Earnings Release
Similar to KURN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
As of Today at 20:41 UTC, shares in Kuros Biosciences AG are trading at CH₣22.56. This share price information is delayed by 15 minutes.
Shares in Kuros Biosciences AG last closed at CH₣22.56 and the price had moved by +12.8% over the past 365 days. In terms of relative price strength the Kuros Biosciences AG share price has outperformed the FTSE Global All Cap Index by +6% over the past year.
The overall consensus recommendation for Kuros Biosciences AG is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreKuros Biosciences AG does not currently pay a dividend.
Kuros Biosciences AG does not currently pay a dividend.
Kuros Biosciences AG does not currently pay a dividend.
To buy shares in Kuros Biosciences AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣22.56, shares in Kuros Biosciences AG had a market capitalisation of CH₣883.88m.
Here are the trading details for Kuros Biosciences AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: KURN
Based on an overall assessment of its quality, value and momentum Kuros Biosciences AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kuros Biosciences AG is CH₣38.00. That is 68.44% above the last closing price of CH₣22.56.
Analysts covering Kuros Biosciences AG currently have a consensus Earnings Per Share (EPS) forecast of $0.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kuros Biosciences AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.45%.
As of the last closing price of CH₣22.56, shares in Kuros Biosciences AG were trading -16.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kuros Biosciences AG PE ratio based on its reported earnings over the past 12 months is 102.09. The shares last closed at CH₣22.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kuros Biosciences AG's management team is headed by:
- Clemens van Blitterswijk - NEC
- Joost de Bruijn - CEO
- Leanna Caron - NVC
- Michael Grau - CFO
- Alistair Irvine - EXB
- Pascal Longlade - EXB
- Philippe Saudan - EXB
- Frank-Jan van der Velden - EXB
- Scott Bruder - NED
- Oliver Walker - NED